Foundation Medicine Inc, a cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine care, will present data using its Next-Generation Sequencing (NGS) approach to identify novel mutations with clinical utility in routine cancer specimens at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden. These data will be presented by Gary Palmer, MD, JD, MBA, MPH, senior vice president, medical affairs and commercial development, Foundation Medicine, in an oral presentation on Sunday, September 25, 2011, at 9:00 am (CEST) during the “personalized medicine” proffered paper session, abstract number 800.

“We look forward to sharing data on our comprehensive pan-cancer diagnostic test with members of the European clinical oncology community,” said Palmer. “As additional mutations driving patients’ cancers are discovered and more targeted cancer therapies are developed to target these specific mutations, there is an even greater need for comprehensive cancer genome analysis to help inform treatment recommendations. Foundation Medicine’s test detects genomic alterations in relevant cancer genes, including many that are missed using conventional hot spot analysis, at a level of sensitivity and specificity that makes this a clinically relevant test. Using NGS for comprehensive molecular profiling of small amounts of paraffin-embedded cancer tissue, we are able to determine patients’ cancer subtypes to inform targeted therapy selection for each patient.”

Source: Foundation Medicine